Results 211 to 220 of about 390,111 (338)

Requirement and functional redundancy of Ib subgroup bHLH proteins for iron deficiency responses and uptake in Arabidopsis thaliana.

open access: yesMolecular Plant, 2013
Ning Wang   +8 more
semanticscholar   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez   +17 more
wiley   +1 more source

En krog ind i billedet [PDF]

open access: yes, 1998
Poulsen, Ib
core  

Spatiotemporal Transmission Characteristics of Global Monkeypox - Worldwide, January 2022-September 2025. [PDF]

open access: yesChina CDC Wkly
Yin W   +11 more
europepmc   +1 more source

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Disease Overview The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy.
Guillermo Garcia‐Manero
wiley   +1 more source

Prevalence in the United States of aac(6′)-Ib-cr Encoding a Ciprofloxacin-Modifying Enzyme

open access: yesAntimicrobial Agents and Chemotherapy, 2006
Chinsu Park   +4 more
semanticscholar   +1 more source

Quizartinib in Combination With FLAG‐IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG‐QUIDA): A PETHEMA Phase I‐II Trial

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Quizartinib is a tyrosine kinase inhibitor with single agent activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and has demonstrated efficacy in first‐line therapy when combined with intensive chemotherapy in both FLT3 ITD‐negative and positive AML.
Teresa Bernal   +29 more
wiley   +1 more source

Readiness Level of Spanish Labs to Detect Mpox Clade Ib: A Nationwide EQA. [PDF]

open access: yesJ Med Virol
De Salazar A   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy